This is a trial to evaluate the safety and effect of three intravenous (IV) doses of NTS-521 for the early recovery treatment of acute ischemic stroke (AIS). Participants will be followed for 90 days.
Inclusion Criteria:
Exclusion Criteria:
s.oshana@neurotraumasciences.com18603022074
Sponsor, Clinical Monitors
0.9% saline solution
Low Dose NTS-521 in 0.9% saline delivered IV
Medium Dose NTS-521 in 0.9% saline delivered IV
High Dose NTS-521 in 0.9% saline delivered IV
a.ward@neurotraumasciences.com910-616-8586
Single Ascending Dose Safety and Tolerability of NTS-104 Healthy Adults
A Study to Assess the Efficacy, Safety, and Pharmacokinetics of TB006 in Participants With Acute Ischemic Stroke
Field Randomization of Nerinetide (NA-1) Therapy in Early Responders
Intravenous N-Acetylcysteine for the Treatment of Acute Ischemic Stroke
A Study to Evaluate the Safety and Potential Efficacy of LT3001 Drug Product in Subjects With AIS
Effectiveness and Safety Trial of a New Ischemic Stroke Treatment Within 24 Hours From Stroke Onset (NEST-2)
A Study to Evaluate the Safety and Efficacy of Multiple Doses of LT3001 Drug Product in AIS Subjects
A Study to Evaluate the Safety and Efficacy of LT3001 Drug Product in Subjects AIS Undergoing EVT